The upgrade of NuCana plc (NASDAQ: NCNA) to a target price of $0.8415 reflects renewed investor confidence following promising early data from its clinical pipeline, particularly in biliary tract and pancreatic cancers. With strengthened cash reserves extending the company’s runway into 2026 and clear strategic focus on advancing NUC-3373, NCNA demonstrates improved fundamentals. The stock is currently undervalued relative to its peer group and pipeline potential, justifying a re-rating to better align with projected milestones and risk-adjusted asset value.